Page last updated: 2024-11-06

droxicam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Droxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat pain and inflammation. It is a derivative of oxicam, a class of drugs that are known for their analgesic and anti-inflammatory properties. Droxicam works by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. Droxicam is typically taken by mouth, and it is available in both tablet and capsule forms. The drug is typically well-tolerated, but it can cause side effects such as stomach upset, nausea, and dizziness. It is important to note that droxicam should not be taken by people who are allergic to oxicams or other NSAIDs, or by people who have a history of stomach ulcers or bleeding. Research on droxicam focuses on its potential benefits in treating a variety of conditions, including osteoarthritis, rheumatoid arthritis, and menstrual cramps. Studies have shown that droxicam is effective in reducing pain and inflammation in these conditions. However, further research is needed to understand the long-term safety and efficacy of droxicam. Droxicam is studied to understand its mechanism of action, potential therapeutic applications, and to explore its safety profile.'

droxicam: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65679
CHEMBL ID1213420
CHEBI ID76133
SCHEMBL ID24974
MeSH IDM0140799

Synonyms (48)

Synonym
chebi:76133 ,
CHEMBL1213420
drogelon
ombolan
e-3128
ferpan
2h,5h-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3h)-dione, 5-methyl-3-(2-pyridinyl)-, 6,6-dioxide
e 318
droxicamum [latin]
brn 6006252
5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3h)-dione 6,6-dioxide
5-methyl-3-(2-pyridinyl)-2h,5h-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3h)-dione 6,6-dioxide
droxicam [inn]
c16h11n3o5s
droxicam (inn)
D07267
90101-16-9
droxicam
5-methyl-6,6-dioxo-3-pyridin-2-yl-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4-dione
AKOS016014050
f24ado1e2d ,
unii-f24ado1e2d
droxicamum
FT-0630972
droxicam [mart.]
droxicam [who-dd]
5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino(5,6-))(1,2)benzothiazine-2,4(3h)-dione 6,6-dioxide
droxicam [mi]
smr004701304
MLS006010209
SCHEMBL24974
5-methyl-3-(pyridin-2-yl)-2h,5h-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3h)-dione 6,6-dioxide
5-methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4(3h,5h)-dione 6,6-dioxide
precam
5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4-(3h)dione-6,6-dioxide
OEHFRZLKGRKFAS-UHFFFAOYSA-N
DB09215
DTXSID70238035
8-methyl-5-(pyridin-2-yl)-3-oxa-9lambda6-thia-5,8-diazatricyclo[8.4.0.0^{2,7}]tetradeca-1(14),2(7),10,12-tetraene-4,6,9,9-tetrone
GS-3100
8-methyl-5-(pyridin-2-yl)-3-oxa-9$l^{6}-thia-5,8-diazatricyclo[8.4.0.0^{2,7}]tetradeca-1(10),2(7),11,13-tetraene-4,6,9,9-tetrone
5-methyl-3-(pyridin-2-yl)benzo[5,6][1,2]thiazino-[3,4-e][1,3]oxazine-2,4(3h,5h)-dione 6,6-dioxide
A860904
Q5308701
5-methyl-3-(pyridin-2-yl)-3-hydro-2h,5h-benzo[5,6][1,2]thiazino[3,4-e][1,3]oxazine-2,4-dione 6,6-dioxide
5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino[5,6-c][1,2]benzothiazine-2,4(3h)-dione 6,6-dioxide;droxicam
HY-107345
CS-0028188

Research Excerpts

Overview

Droxicam is a new nonsteroidal anti-inflammatory drug that is a pro-drug of piroxicam. It also acts as an ex vivo platelet aggregation inhibitor in the dog.

ExcerptReferenceRelevance
"Droxicam is a new non-steroid anti-inflammatory drug that is a pro-drug of piroxicam. "( Pharmacokinetic profile of droxicam.
Martínez, L; Sánchez, J, 1991
)
2.02
"Droxicam is a nonsteroidal anti-inflammatory drug that is a pro-drug of piroxicam. "( The effect of antacid and ranitidine on droxicam pharmacokinetics.
Bartlett, A; Costa, A; Martínez, L; Roser, R; Sagarra, R; Sánchez, J, 1992
)
1.99
"Droxicam is a new anti-inflammatory drug which is a pro-drug of piroxicam and possesses delayed absorption kinetics. "( Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.
Bartlett, A; Costa, A; Martinez, L; Roser, R; Sagarra, R; Sanchez, J,
)
1.82
"Droxicam is a new nonsteroidal anti-inflammatory drug that is a pro-drug of piroxicam. "( The influence of gastric emptying on droxicam pharmacokinetics.
Bartlett, A; García-Barbal, J; Martínez, L; Roser, R; Sagarra, R; Sánchez, J, 1989
)
1.99
"Droxicam also acts as an ex vivo platelet aggregation inhibitor in the dog."( Pharmacological profile of droxicam.
Esteve, J; Farré, AJ; Roser, R, 1988
)
1.29

Toxicity

ExcerptReferenceRelevance
"This study analyses the results of 8 randomized, controlled clinical trials and one open study carried out with droxicam (a new NSAID, pro-drug of piroxicam), comparing the adverse events and gastrointestinal tolerance of this compound against those of the control drugs used in these trials."( Adverse events with droxicam in the early clinical trials.
Bartlett, A; Costa, A; Estiarte, R; Estruch, J; Sánchez, J; Soucheiron, C, 1991
)
0.82

Pharmacokinetics

A single oral dose pharmacokinetic study in a group of 10 elderly healthy volunteers was performed to evaluate the potential effect of age on the absorption, distribution and elimination of droxicam.

ExcerptReferenceRelevance
" After a single 10mg dose the value of Tmax was higher than that reported for piroxicam (10mg)."( Pharmacokinetic profile of droxicam.
Martínez, L; Sánchez, J, 1991
)
0.58
"A single oral dose pharmacokinetic study in a group of 10 elderly healthy volunteers was performed to evaluate the pharmacokinetic profile and the potential effect of age on the absorption, distribution and elimination of droxicam."( A pharmacokinetic study to evaluate the profile of droxicam in elderly healthy volunteers after a single oral dose of 20mg.
Bartlett, A; Harrison, FJ; Hosie, J; Kelly, J; Sánchez, J, 1991
)
0.72
" A pharmacokinetic test to compare the plasma levels of piroxicam obtained in rat and dog was then made after oral administration of droxicam and piroxicam."( Pharmacokinetics of droxicam in rat and dog.
Esteve, A; Martínez, L; Roser, R; Sagarra, R, 1986
)
0.8
" The pharmacokinetic parameter values (mean +/- RSD) of piroxicam after administration of droxicam alone were: AUC0-->infinity = 125."( A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.
Maya, MT; Morais, JA; Pais, JP; Ruas Da Silva, J,
)
0.58

Bioavailability

Droxicam is a prodrug of piroxicam with a slower rate of absorption, but with the same bioavailability within the range of therapeutic doses. As this absorption is in direct relation to the depth of the lesions, it can be considered from the results of this study that the lesser lesive effect of droXicam on the gastric mucosa when compared to that of pIROxicham is due to the fact that, owi.

ExcerptReferenceRelevance
" Absorption and elimination of droxicam are independent of the administered dose and the bioavailability of droxicam and piroxicam was equal."( Pharmacokinetic profile of droxicam.
Martínez, L; Sánchez, J, 1991
)
0.86
" In this study, the comparative bioavailability of the two compounds was investigated."( Cross-over study of the bioavailability of a new NSAID (droxicam) versus piroxicam in healthy volunteers following single and multiple dose administration.
Bartlett, A; Costa, A; Martinez, L; Roser, R; Sagarra, R; Sanchez, J,
)
0.38
" It may be concluded from these results that absorption, elimination and bioavailability kinetics of droxicam are independent of the administered dose."( Single and multiple dose pharmacokinetics of a new NSAID (droxicam) in healthy volunteers.
Bartlett, A; Garcia-Barbal, J; Martinez, L; Roser, R; Sagarra, R; Sanchez, J,
)
0.59
" These results indicate that absorption rate of droxicam has been modified but bioavailability does not suffer modification in conditions of altered gastric emptying."( The influence of gastric emptying on droxicam pharmacokinetics.
Bartlett, A; García-Barbal, J; Martínez, L; Roser, R; Sagarra, R; Sánchez, J, 1989
)
0.81
" The bioavailability of both drugs was equal."( Comparative study of the multiple dose pharmacokinetics and the tolerance of a new NSAID (droxicam) versus piroxicam in healthy volunteers.
Bartlett, A; Costa, A; Estruch, J; García-Barbal, J; Martínez, L; Puig, S; Roser, R; Sagarra, R; Sánchez, J, 1988
)
0.5
" As this absorption is in direct relation to the depth of the lesions, it can be considered from the results of this study that the lesser lesive effect of droxicam on the gastric mucosa when compared to that of piroxicam is due to the fact that, owing to its hydrolysis to piroxicam the absorption rate is slower."( Comparative light and electron microscopic observations of the lesive effects of two non-steroid anti-inflammatory drugs plus stress on rat gastric mucosa.
Castell, O; Colombo, M; Esteve, J; Palacios, G; Roser, R, 1987
)
0.47
" It is concluded that droxicam is a prodrug of piroxicam with a slower rate of absorption, but with the same bioavailability within the range of therapeutic doses."( Pharmacokinetics of droxicam in rat and dog.
Esteve, A; Martínez, L; Roser, R; Sagarra, R, 1986
)
0.91
" These results indicate that concurrent administration of the antacid does not significantly change the bioavailability and pharmacokinetics of droxicam."( A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.
Maya, MT; Morais, JA; Pais, JP; Ruas Da Silva, J,
)
0.56

Dosage Studied

ExcerptRelevanceReference
"In this histological study it has been demonstrated that a single-dose administration of piroxicam, at the same dosage (4 mg/kg) as droxicam, has a greater erosive potential on the gastric mucosa of rats later exposed to cold stress."( Comparative light and electron microscopic observations of the lesive effects of two non-steroid anti-inflammatory drugs plus stress on rat gastric mucosa.
Castell, O; Colombo, M; Esteve, J; Palacios, G; Roser, R, 1987
)
0.48
" The results were compared with those obtained treating a similar group of patients with tenoxicam, at the same dosage of 20 mg/day, orally administered."( [Efficacy of and tolerance to a new NSAID in the treatment of arthrosis: droxicam. Randomized study versus tenoxicam].
Chevallard, M; Colombo, B; Venegoni, C, 1993
)
0.52
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
cyclooxygenase 1 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
hepatotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (15.22)18.7374
1990's31 (67.39)18.2507
2000's4 (8.70)29.6817
2010's4 (8.70)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.34 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (19.61%)5.53%
Reviews5 (9.80%)6.00%
Case Studies17 (33.33%)4.05%
Observational0 (0.00%)0.25%
Other19 (37.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]